|
|
|
| Webinar: Development of an Off-the-Shelf γδ T-Cell Platform for Allogenic Cell Therapies | Unlock the future of cell therapy with Miltenyi! Join our webinar to explore how γδ T cells are driving next-generation, off-the-shelf allogeneic therapies. Discover their unique advantages, learn engineering strategies to overcome immunological hurdles, and see a real-world case study of a successful therapeutic candidate. Don’t miss this chance to gain insights into the future of immuno-oncology. Click here to learn more. |
|
|
FOCUS ON TRANSLATIONAL RESEARCH |
|
|
|
In this episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible, even for non-experts. |
|
|
|
|
| Guidelines For Comparing SYBR Green Master Mixes | Infographic | Applied Biosystems by Thermo Fisher Scientific, qPCR | A straightforward protocol for comparing qPCR master mixes is key to ensuring reliable results. See how to evaluate specificity, PCR efficiency, and precision to ensure accurate gene expression analysis. |
|
|
|
|
| Webinar: Evolving Gene Editing for Rare Disease Drug Development | Danaher is partnering with leading academic and clinical research institutes focused on the development of a novel platform approach to gene editing aimed at accelerating the delivery of therapies and creating economies of scale to treat ultra-orphan conditions. We will explore how to create scalable models for efficient manufacturing and broader patient access and formulate regulatory and clinical strategies to address rare disease challenges. Learn more. |
|
|
TRANSLATIONAL RESEARCH SOLUTIONS |
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
